Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2005-10-14

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.4088/JCP.V66N1012PMID 16259543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features

  2004cited by this paper
• Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.

  2003cited by this paper
• Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

  2003cited by this paper
• Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics.

  2003cited by this paper
• Olanzapine-fluoxetine combination in treatment-resistant depression

  2002cited by this paper
• ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS

  2001cited by this paper
• A novel augmentation strategy for treating resistant major depression.

  2001cited by this paper
• Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders.

  2000cited by this paper
• Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

  2000cited by this paper
• Treatment resistant depression: methodological overview and operational criteria.

  1999cited by this paper
• Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

  1999cited by this paper
• Treating antidepressant nonresponders with augmentation strategies: an overview.

  1998cited by this paper
• When at first you don't succeed: sequential strategies for antidepressant nonresponders.

  1997cited by this paper
• Treatment algorithms in treatment-resistant depression.

  1996cited by this paper
• Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs

  1996cited by this paper
• Definition and epidemiology of treatment-resistant depression.

  1996cited by this paper
• Progress in Treatment-Resistant and Treatment-Refractory Depression: We Still Have a Long Way to Go

  1994cited by this paper
• Treatment-resistant depression: definition and treatment approaches.

  1990cited by this paper
• A Rating Scale for Drug-Induced Akathisia

  1989cited by this paper
• Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine.

  1989cited by this paper
• How to examine patients using the Abnormal Involuntary Movement Scale.

  1988cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper
• The assessment of anxiety states by rating.

  1959cited by this paper

• Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.

  2025cites this paper
• A New Era for Esketamine in Managing Treatment-Resistant Depression: A Systematic Review of Its Use From Adjunct to First-Line Therapy

  2025cites this paper
• A systematic review of augmentation strategies for patients with major depressive disorder.

  2025cites this paper
• Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis

  2023cites this paper
• Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

  2023cites this paper
• A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics

  2023cites this paper
• Rethinking the medication management of major depression

  2023cites this paper
• Augmentation Strategies For Treatment Resistant Major Depression: A Systematic Review And Network Meta-Analysis.

  2022cites this paper
• Treatment resistance in psychiatry: state of the art and new directions

  2021cites this paper
• Intranasal esketamine: From origins to future implications in treatment-resistant depression.

  2021cites this paper
• Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.

  2021cites this paper
• Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium

  2021cites this paper
• Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis

  2020cites this paper
• Predicting trajectories of symptom change during and following treatment in adolescents with Unipolar Major Depression

  2020cites this paper
• Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines

  2020influential citation
• Pharmacological Treatments for Patients with Treatment-Resistant Depression

  2020cites this paper
• A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination

  2019cites this paper
• Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression

  2019cites this paper
• Treatment-resistant depression - recommendations of the National Consultant in the field of psychiatry.

  2019cites this paper
• Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder

  2019cites this paper
• Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression

  2018cites this paper
• Assessing 42 inflammatory markers in 321 control subjects and 887 major depressive disorder cases: BMI and other confounders and overall predictive ability for current depression

  2018cites this paper
• Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics

  2018cites this paper
• Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.

  2017cites this paper
• Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis

  2017cites this paper
• Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.

  2017cites this paper
• The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder

  2017cites this paper
• Double-blind switch study of vilazodone in the treatment of major depressive disorder

  2017cites this paper
• The combination of escitalopram and aripiprazole: Investigation of psychomotor effects in rats

  2017cites this paper
• Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials

  2017influential citation
• Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

  2016cites this paper
• Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes.

  2016cites this paper
• Behandlung depressiver Störungen

  2016cites this paper
• [Potentiation strategies].

  2016cites this paper
• Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics

  2015cites this paper
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

  2015cites this paper
• Fixed dose-combination products in psychiatry: Systematic review and meta-analysis

  2015influential citation
• Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

  2015cites this paper
• Olanzapine and fluoxetine combined as therapy for treatment-resistant depression: a systematic review

  2015cites this paper
• Pharmacological Management of Treatment‐Resistant Unipolar Depression

  2015cites this paper
• A simple and automated online SPE-LC-MS/MS method for simultaneous determination of olanzapine, fluoxetine and norfluoxetine in human plasma and its application in therapeutic drug monitoring

  2015cites this paper
• Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

  2015cites this paper
• Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?

  2015cites this paper
• Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.

  2015cites this paper
• Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies

  2015cites this paper
• A Review of the Role of Antipsychotics as an Augmentation Agentor Treatment Option for Patients with Treatment Resistant UnipolarDepression

  2015cites this paper
• Comparative Studies of the Efficacy of Combinations of SSRI Antidepressants and Antipsychotics in the Treatment of Recurrent Depressive Disorder

  2014cites this paper
• Drug safety evaluation of olanzapine/fluoxetine combination

  2014cites this paper
• Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder

  2014cites this paper
• Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder

  2014cites this paper
• Augmentation in Treatment Resistant Depression: A stab in the dark? Outline

  2014cites this paper
• The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

  2014cites this paper
• [Treatment-resistant depression: state of the art Part II. Treatment].

  2014cites this paper
• The Role of Atypical Antipsychotic Therapy for Patients with Treatment-Resistant Bipolar Depression

  2014cites this paper
• Management of major depressive disorder

  2014cites this paper
• The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats

  2014cites this paper
• Use of second generation antipsychotics for treatment-resistant major depressive disorder

  2014cites this paper
• National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

  2014cites this paper
• La asociación psiquiátrica de América Latina

  2014cites this paper
• PPT Polypharmazie in der Behandlung depressiver Störungen

  2014cites this paper
• Spatial and temporal patterns of postsynaptic genes and proteins expression by multiple receptors targeting agents: unraveling the impact of multitargeting approach on dopamine-glutamate mediated synaptic plasticity

  2014cites this paper
• Efficacy and Safety of Antipsychotics for the Treatment of Major Depressive Disorder in Adolescents and Adults: Current Issues and Clinical Perspective

  2014cites this paper
• The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression

  2013cites this paper
• University Medical School of Naples "Federico II" Department of Neuroscience, Reproductive and Odontostomatologic Sciences

  2013cites this paper
• The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression

  2013cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders

  2013cites this paper
• Second-generation antipsychotics in the treatment of major depressive disorder: current evidence

  2013cites this paper
• Korean Medication Algorithm for Depressive Disorder (IV): Child and Adolescent/The Elderly/Female

  2013cites this paper
• Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

  2013cites this paper
• 5-HT2A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system

  2013cites this paper
• Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature

  2013cites this paper
• Pharmacological interventions for treatment-resistant depression in adults.

  2013cites this paper
• Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes

  2013influential citation
• Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach.

  2013cites this paper
• Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression

  2013cites this paper
• Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy

  2013cites this paper
• Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment.

  2013cites this paper
• Mode of action of asenapine vs. other antipsychotic drugs : an experimental analysis

  2012cites this paper
• Pharmacological treatment of unipolar depression.

  2012cites this paper
• La psicosis única revisitada: De la nosotaxia a la nosología

  2012cites this paper
• If at First You Don’t Succeed

  2012influential citation
• Revisiting unitary psychosis, from nosotaxis to nosology

  2012cites this paper
• Emerging drugs for major depressive disorder

  2012cites this paper
• Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?

  2012cites this paper
• [The comparative study on the efficacy of the combination of serotonin reuptake inhibitor antidepressants and antipsychotics in the treatment of recurrent depressive disorders].

  2012cites this paper
• Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy

  2012cites this paper
• La psicosis única revisitada. De la nosotaxia a la nosología

  2012cites this paper
• Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination: An Analysis of 2 Adult Studies in Treatment-Resistant Depression

  2011cites this paper
• Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: Consecutive case series

  2011cites this paper
• Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.

  2011cites this paper
• La depressione maggiore resistente: update delle strategie di trattamento farmacologico

  2011cites this paper
• Revisión de la literatura médica sobre el manejo de las depresiones resistentes/refractarias al tratamiento

  2011cites this paper
• Augmentation von Antidepressiva mit atypischen Antipsychotika bei Nonresponse auf eine Antidepressiva-Monotherapie

  2011cites this paper
• Antipsychotics as antidepressants: what is the mechanism?

  2011cites this paper
• Response rates to fluoxetine in subjects who initially show no improvement.

  2011cites this paper
• Therapeutic options in treatment-resistant depression

  2011cites this paper
• Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

  2011cites this paper
• Second-generation antipsychotics in major depressive disorder: update and clinical perspective

  2011cites this paper
• Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

  2010cites this paper
• Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder

  2010cites this paper